Is Vaidya Sane overvalued or undervalued?

As of 29 August 2025, Vaidya Sane's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. Despite this change, the company is still considered overvalued. The key ratios highlight this situation: the PE ratio stands at 51.68, the EV to EBITDA ratio is 27.71, and the PEG ratio is remarkably low at 0.12, suggesting that the stock may not be justified at its current price. When compared to peers, Vaidya Sane's valuation metrics are significantly higher than those of Sun Pharma, which has a PE ratio of 33.34 and an EV to EBITDA of 22.54, and Cipla, which boasts a more attractive PE ratio of 23.82 and an EV to EBITDA of 16.8. Although Vaidya Sane has outperformed the Sensex with a year-to-date return of 104.22% compared to the Sensex's 3.31%, this performance does not mitigate the overvaluation indicated by its ratios relative to industry peers.